Jump to:

Council for Tobacco Research

80% of `Hopeless' Carcinoma Patients Respond Well to 4-Drug Combination American Druggist [St Describes Effect of Drug Therapy]

Date: 07 Sep 1970
Length: 1 page
11314552
Jump To Images
snapshot_ctr 11314552_4552

Fields

Type
SCIENTIFIC ARTICLE
ABSTRACT
Master ID
11314459-4557
Related Documents:
Request
37(B)
Depository Date
30 Sep 1996
Named Person
Amer Druggist
Miroquesada, O., Nih
Author
Invenex Pharmaceuticals
Box
212
UCSF Legacy ID
eah6aa00

Document Images

Text Control

Highlight Text:

OCR Text Alignment:

Image Control

Image Rotation:

Image Size:

Page 1: eah6aa00 Log in for more options!
lIPO HEPIN R (Riker Labs.) (See Catalog Under Riker Laboratories) Aul. I ml., 10,00o U%ml. 70s (#L•172) -402-0 Ampu~ 10mt89 0 00GIU mi. AWP 50.04 50s [#L-176) [#NDC-89-406-50) ea. AWP 100•02 Viai, 10 mi., 1000 U, ml. [#L-110) 10 m11~500oUami)(~i-150] AWP .78 (#NDC-89-415•01] ea. AWP 3.06 4 ml., 10,000 U/mi. [#L-114] 423 AWP ml [ mND 2-46 • [#L-115) 10 000 U 5 (#NDC-89-425-01] ea. AWP 3.06 2 ml., 20.000 U ml. [#L-122] 5[m~D 2090 02Ulmlea[#L•125 AWP 2.46 10 mND 2~ 000 U ml e(#rL•120jAWP 5.26 [#NDC-89•438-01[ ea. AWP 10.50 2 ml., 40,000 U ~mL. [#L-142] 5(N mD 40,00G UOmI (#L•145)AWP 4.20 [#NDC-89-445-01] ea. AWP 10.50 MEDIHALER-EPI(Riker Laboratories) (See Catalog Under Riker Laboratoriesl Vial w Adapter 15 mL [#W-142) [#NDC•B9•755•21) ea, AWP 2.70 Vial only. 15 ml (#M•143] (#NDC•89•755-11; ea. AWP 2,40 MEDIHALER•ERGOTAMINE R (Riker Labs.` (See Catalog Under Riker Laboratones : Vial w Adapter. 2.5 mi (*M-122; (#NDC-89-762-21] ea. AWP 5.10 MEIDHALER-ISO R (Riker Laboratories, (See Catalog Under R(ker Laboratorie s Vial w Adapter, #M-144; 15 mi. U [#ND -89-785•21) ea. AWP 2.7G V al only, 15 mL. [#M-145? Vial w#Adap8er785 11] ea. AWP 2.40 22.5 mi [#NDC-89-782-211 ea. AWP 3.30 Vial only, 22.5 mi. [#NDC-89-782-11] ea. AWP 3-00 NEUTRAPEN B (Riker Laborator es (See Catalog Unaer Riker Laborator es' Vial. Single dose w •diluent [# N-105'. [#NDC•89-530-01) ea. AWP 6-6C NORFLEX R (Riker Laboratones'r (See Catalog Under Riker Laborator e s' In)ectable. Ampul. 2 mi. 6s [#N•131~ 505#[#N•$32540-06 ea. AWP 6.00 [#NDC-89-540-50] ea. AWP 41.70 Tablet. 50s [#N-125] 500s [Dn_8~~221•05) ea . AWP 7.50 [#NDC-89-221-50] ea. AWP 72.00 NORGESIC R (Riker Laboratories) (See Catalog Uinder Riker Laboratories) Tablet, 100s (#N-1411 d*NIIC•89-235-101 ea. AWP 6.90 5r70s r#N 142 t*N.DC-85-235•S0; ea. AWP 32 76 PENTOXYLON B (R ker Laboratories , (See Catalog Under Riker Laborat Tablet, 100s f*P-1211 ories; 1000ND~P9i231-10) ea. AWP 3.60 [#NDC-89-251-80) ea. AWP 30.60 RAUWIL010 R (Riker Laboratories) (See Catalog Under Riker Laboratories, Inc,) Tablet, 2 mg., 605 (#R-100) 1000s [#RI335-80] ea. AWP 3.90 [#NDC-89-265-80] ea- AWP 52.80 RAUWILOtD (Rike (See Cata Tablet, W/HEXAMETH r Labs,. log Under Rike ONIUM R r Laborat ories) 100s [#R-151) [#NDC-89-295•10] ea. AWP 4.50 RAUWIL0ID W/YERILOID R (Riker Labs.) (See Catalog Under Riker Laboratories) Tabl et, 100s (#R-131) j-10) ea. R 3 OS~ O AWP 9.60 O rY I 3 I (#NDC-89•281-80) ea, AWP 78.00 SEDAMYL R (Riker Laboratories) (See Catalog Under Riker Laboratories) Tablet, 10os [!#S-101] [#NDC•B9-311•10) ea. AWP 4.50 SODIUM VERSENATE R (Riker Laboratories) (See Catalog Under Riker Laboratories. Inc.) Ampul, 5'ml, 6s (#S191J• [rYNDC•89•57006) ea. AWP B70 SOMBULEX E (Riker Laboratories) (See Catalog Under Riker Laboratories, Inc.) Tablet. MOLLIFENE (Pieiffer Co.) (See Pfeiffer Catafog (nsert, Ear Drop. 24 cc. 8.80 3005 IrkS•181) TRACE (Lorvic Corp.) da1NDC-89-325-10) ea. AWP 4.20 Solut on. TITRAC (Riker Laboratories) 2 oz. bottle. ea. 2.25 (See Catalog Under Riker Laboratories, Inc.) ' Tablet, Individually Sealed 40s (#T-110) 5-04] ea. AWP ~89-3 5 [fi ND .90 PRICE ADVANCES 0 7 ( [+(tNDC•89•3515-66] ea. AWP .96 1ABEE CDF (Pfeiffer Co.) 100s (#T-111) (See Pfe(ffer Catalog Insert) [#NDC-89-355-10] ea. AWP ' 1.80 4 oz. 8.00 500s (#T-113-i BOYOL SALVE (Pfeiffer Co.) E#NDC•89-355•50] ea. AWP 8.10 (See Pfeiffer Catalog Insert) 1000s 1#7-1121 1 oz. 6.60 [#NDC-89-355•80] ®a. AWP 15.30 CALAMYCIN (Pfeiffer Co.) Liquid, 12 fi. oz. [#T-125) (See Pfeiffer Catalog Insert) Lot on, 4 oz 9.00 b950•12] ea, AWP RNDC-89 [ 1.74 KALMETS (Pfeifter Co.) a ( ULO R (See Catalog Under Riker Laboratories) (See Pfeiffer Catalog Insert, Capsule, 20s 7.20 Liquid, 12 fi. oz. (#U•104) KADDENE C (Pfeiffer Co I (See Pfe ffer Catalog Insert) (#NDC•89•970-12] ea, AWP 5.64 4 oz. 11.85 1 gal. [#U-106; tULFADIAZINE R (Parke-Dans; [#NDC•89.970-28; ea, . AWP ULOGESIC ]; (Riker Labs.) 52.80 Tablet. 0.5 Gm. 100s (#25-804-4) a (See Catalog Under Riker Laboratories) (#NDC•11-804•4] ea. *2.31 Tab(et. AWP 2.77 s (#U-109) I00 1o00s [#25•804-111 ( Labratoriesl AWP ULOMINICNR R~ e67o 4.50 [#NDC•71-804-11) ea. *19.20 AWP 23.04 (See Catalog Under Riker Laboratories, Inc.) Liquid SULFAPYRIDINE R (Parke•Davisl 0.5 Gm.. (7.7 gr.) Tab(et 16 fl. oz. [#U•112) . 100s 1#25•785-41,, [#NDC-89•980-16) ea. AWP 6.00 (#NDC-71-785-4) ea *2.49 YERILO[D R (Riker Laboratories) . AWP 2.99 (See Catalog Under Riker Laboratories, Inc.) 1000s [#25•785-111 Tablet. [AFNDC•71•785•11) ea. *19.50 2mg.. AWP 23.40 10os (#V-1211 SURITAL B (Parke-Davis) (#NDC-89-381•10) ea AWP 5.40 Ampoules. 3mg., I Gm. [#3-264-11 IODs [#V-131) [#NDC•89•385-10) ea, AWP 7.20 [#FNDC•71-1262•11 ea AWP 1.19 Steri-Vial, (#35•64-11 I Gm , [#NDC-71•1098•1) ea *.99 NEW PRODUCTS W Diluent. [#'35-64-2' D 7 09 2 AWP 1.15 145 KODET (Pfeiffer Co.. C- ; ea [#N 1•1 8- * AWP 1.74 (See Pfeiffer Catalog Insert) Tabtet. 18s 9.00 LAROBEC (Roche Laboratories, TRIPLE SULFAS R (Parke-Davis, Tablet. 1000s (#25-854-11', Tablet. 100s ea 4.85 [a#NT)CJ1-a54-11' ea *18.69 80% of 'hopeless' carcinoma patients respond well to 4-drug combination A combination of 4 drugs helps patients suffering from advanced carcinoma, according to Dr. Oscar NIir(i-Quesada, )r, director of the National Institutes of Health, Lima. Peru. The drugs are mitonlrcin C. 5- fluorouracil, c}-clophosphamide, and SEE .• - ,a~.nve~nex ;: ,;;PHARMACEUTICAtS CATALOG in 1970 BLUE BOOK PAGES 323-324-325 OVER ONE HUNDRED FIFTY QU4LRY PHARMACEUTICALS methotrexate. Dextrose. 51,"r in water, is used as a stablizing agent to prevent reactions among the drugs The combination is infused at a rate of 120 to 150 drops per minute for approximately 1% hours once or twice aweet;. This therapy is con- tinued for 8 weeks. The research team of 18 ph,, cians, led by Dr. lt'liro-Quesada stuclied 43 "hopeless" cases. The patients had a>.•ariety of carcinomas including mamman•, bronchogenic. and pancreatic. All had been treatecl previously by surger}•, radiation, or other drugs. Of the 43 patients. 80"', re- sponded well to the therapy, said Dr. M iro-Quesada. In even the most advanced cases that responded, a 3 month to 6 month prolongation oi life occurred, he said. r AMERICAN DRUGGIST • September 7, 1970 Ej'4,lno Gode • 95

Text Control

Highlight Text:

OCR Text Alignment:

Image Control

Image Rotation:

Image Size: